Selective inhibitors of CYP24A1 represent an important synthetic target in a search for novel vitamin D compounds of therapeutic value. In the present work, we show the synthesis and biological properties of two novel side chain modified 2-methylene-19-nor-1,25(OH)2D3 analogues, the 22-imidazole-1-yl derivative 2 (VIMI) and the 25-N-cyclopropylamine compound 3 (CPA1), which were efficiently prepared in convergent syntheses utilizing the Lythgoe type Horner-Wittig olefination reaction. When tested in a cell-free assay, both compounds were found to be potent competitive inhibitors of CYP24A1, with the cyclopropylamine analog 3 exhibiting an 80 to 1 selective inhibition of CYP24A1 over CYP27B1. Addition of 3 to a mouse osteoblast culture sustained the level of 1,25(OH)2D3, further demonstrating its effectiveness in CYP24A1 inhibition. Importantly, the in vitro effects on human promyeloid leukemia (HL-60) cell differentiation by 3 were nearly identical to those of 1,25(OH)2D3 and in vivo the compound showed low calcemic activity. Finally, the results of preliminary theoretical studies provide useful insights to rationalize the ability of analog 3 to selectively inhibit the cytochrome P450 isoform CYP24A1.
|Autori:||Chiellini, Grazia; Rapposelli, Simona; Zhu, J; Massarelli, I; Saraceno, M; Bianucci, ANNA MARIA PAOLA; Plum, La; Clagett Dame, M; Deluca, Hf|
|Titolo:||Synthesis and biological activities of vitamin D-like inhibitors of CYP24 hydroxylase|
|Anno del prodotto:||2012|
|Digital Object Identifier (DOI):||10.1016/j.steroids.2011.11.007|
|Appare nelle tipologie:||1.1 Articolo in rivista|